Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ195MR)

This product GTTS-WQ195MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Cancers, non-small cell lung (NSCLC), Coat's disease research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ195MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4431MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ12977MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ5195MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CAT-8015
GTTS-WQ15555MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ10817MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA M7824
GTTS-WQ10045MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ8752MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ7548MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GC33
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW